1.29
-0.05(-3.73%)
Currency In USD
| Previous Close | 1.34 |
| Open | 1.33 |
| Day High | 1.36 |
| Day Low | 1.28 |
| 52-Week High | 5.92 |
| 52-Week Low | 1.25 |
| Volume | 1.18M |
| Average Volume | 2.02M |
| Market Cap | 88.35M |
| PE | -1.59 |
| EPS | -0.81 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 2.91 |
| Change | -0.05 |
If you invested $1000 in Neuronetics, Inc. (STIM) since IPO date, it would be worth $46.44 as of February 21, 2026 at a share price of $1.29. Whereas If you bought $1000 worth of Neuronetics, Inc. (STIM) shares 5 years ago, it would be worth $72.68 as of February 21, 2026 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 10, 2026 9:34 PM GMT
All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenu
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:30 PM GMT
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the live
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
GlobeNewswire Inc.
Nov 12, 2025 3:33 PM GMT
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 StatesMALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and m